Rostafuroxin

Rostafuroxin
Names
	IUPAC name 21,23-Epoxy-24-nor-5β-chola-20,22-diene-3β,14β,17-triol
	Systematic IUPAC name (1S,3aS,3bR,5aR,7S,9aS,9bS,11aS)-1-(Furan-3-yl)-9a,11a-dimethylhexadecahydro-3aH-cyclopenta[a]phenanthrene-1,3a,7-triol
Identifiers
CAS Number	156722-18-8;
3D model (JSmol)	Interactive image;
PubChem CID	153976;
UNII	P848LCX62B;
CompTox Dashboard (EPA)	DTXSID20870040 ;
	SMILES C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@]4(C5=COC=C5)O)O)C)O;
Properties
Chemical formula	C23H34O4
Molar mass	374.521 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Rostafuroxin is a digitoxigenin analog that has been shown to lower blood pressure in an animal model of hypertension.^[1] It modulates the effects of the enzyme Na⁺/K⁺-ATPase,^[1] which maintains sodium and potassium ion gradients across plasma membranes. Rostafuroxin is being studied in clinical trials for the treatment of essential hypertension.^[2]^[3]

References

^ ^a ^b Ferrari, Patrizia; Ferrandi, Mara; Valentini, Giovanni; Bianchi, Giuseppe (2006). "Rostafuroxin: An ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290 (3): R529 – R535. doi:10.1152/ajpregu.00518.2005. PMID 16467500.
^ Ferrari, Patrizia (2010). "Rostafuroxin: An ouabain-inhibitor counteracting specific forms of hypertension". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1802 (12): 1254–1258. doi:10.1016/j.BBAdis.2010.01.009. PMID 20083196.
^ "Efficacy of Rostafuroxin in the Treatment of Essential Hypertension". clinicaltrials.gov.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.